Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience.
Naseema GangatKristen McCulloughAref A Al-KaliKebede H BegnaMrinal M PatnaikMark R LitzowWilliam HoganMithun Vinod ShahHassan AlkhateebAbhishek A MangaonkarJames M ForanJeanne M PalmerAnimesh D PardananiAyalew TefferiPublished in: British journal of haematology (2022)